

CITATION REPORT

List of articles citing

Sildenafil and endothelial dysfunction in humans

DOI: 10.1161/01.cir.0000156407.59837.c1
Circulation, 2005, 111, 721-3.

Source: <https://exaly.com/paper-pdf/38793493/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. <i>Chest</i> , 2005 , 128, 3065-73	5.3	31
21	For the motion. <i>European Urology</i> , 2006 , 49, 749-750	10.2	1
20	Cardiovascular effects of phosphodiesterase 5 inhibitors. <i>Current Pharmaceutical Design</i> , 2006 , 12, 3485-94	3.3	45
19	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. <i>International Journal of Impotence Research</i> , 2007 , 19, 139-48	2.3	45
18	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. <i>Cardiology in Review</i> , 2007 , 15, 76-86	3.2	52
17	Delayed preconditioning-mimetic actions of exercise or nitroglycerin do not affect haemodynamics and exercise performance in trained or sedentary individuals. <i>Journal of Sports Sciences</i> , 2007 , 25, 1393-401	2.6	11
16	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. <i>European Urology</i> , 2007 , 52, 990-1005	10.2	45
15	Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. <i>British Journal of Pharmacology</i> , 2008 , 153, 886-93	8.6	49
14	Salivary 8-OHdG: a useful biomarker for predicting severe ED and hypogonadism. <i>Journal of Sexual Medicine</i> , 2008 , 5, 1482-91	1.1	19
13	Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. <i>Angiology</i> , 2008 , 59, 549-58	2.1	15
12	Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009 , 297, H387-91	5.2	22
11	Phosphodiesterase 5 inhibitors: are they cardioprotective?. <i>Cardiovascular Research</i> , 2009 , 83, 204-12	9.9	29
10	Daily use of sildenafil improves endothelial function in men with type 2 diabetes. <i>Journal of Andrology</i> , 2012 , 33, 176-80		40
9	Effect of sildenafil citrate on secondary healing in full thickness skin defects in experiment. <i>Bratislava Medical Journal</i> , 2014 , 115, 267-71	1.7	4
8	Diabetic Cardiomyopathy. 2014 ,		2
7	Targeted protection of donor graft vasculature using a phosphodiesterase inhibitor increases survival and predictability of autologous fat grafts. <i>Plastic and Reconstructive Surgery</i> , 2015 , 135, 488-499	2.7	10
6	Haematological changes and wound healing effects of sildenafil citrate in diabetic albino rats. <i>Sokoto Journal of Veterinary Sciences</i> , 2017 , 15, 20	0.4	3

5	Pharmacological preconditioning with phosphodiesterase inhibitor: an answer to stem cell survival against ischemic injury through JAK/STAT signaling. <i>Heart Failure Reviews</i> , 2020 , 25, 355-366	5	7
4	Sexual function in hypertensive patients receiving treatment. <i>Vascular Health and Risk Management</i> , 2006 , 2, 447-55	4.4	3 ¹
3	Heart Attacks. 2006 , 397-431		
2	The Endothelium, Cardiovascular Disease, and Therapy. 409-467		
1	PDE-5 Inhibitors in Protection of Diabetic Heart. 2014 , 323-338		